Requirements for prospective use of omics-based tests in NCl-sponsored trials

被引：0
|
作者：
McShane, L. M. [1 ]
机构：
[1] NCI, Bethesda, MD 20892 USA
来源：
EUROPEAN JOURNAL OF CANCER | 2011年 / 47卷
关键词：
D O I：
10.1016/S0959-8049(11)72604-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S4 / S4
页数：1
相关论文
共 23 条
  • [1] Criteria for use of omics-based predictors in NCI-sponsored clinical trials
    McShane, Lisa A.
    Conley, Barbara A.
    Cavenagh, Margaret M.
    Lively, Tracy G.
    Eberhard, David A.
    Williams, Paul M.
    Bigbee, William L.
    Mesirov, Jill P.
    Polley, Mei-Yin C.
    Kim, Kelly Y.
    Tricoli, James V.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (30)
  • [2] Criteria for the use of omics-based predictors in clinical trials
    McShane, Lisa M.
    Cavenagh, Margaret M.
    Lively, Tracy G.
    Eberhard, David A.
    Bigbee, William L.
    Williams, P. Mickey
    Mesirov, Jill P.
    Polley, Mei-Yin C.
    Kim, Kelly Y.
    Tricoli, James V.
    Taylor, Jeremy M. G.
    Shuman, Deborah J.
    Simon, Richard M.
    Doroshow, James H.
    Conley, Barbara A.
    NATURE, 2013, 502 (7471) : 317 - 320
  • [3] Criteria for the use of omics-based predictors in clinical trials
    Lisa M. McShane
    Margaret M. Cavenagh
    Tracy G. Lively
    David A. Eberhard
    William L. Bigbee
    P. Mickey Williams
    Jill P. Mesirov
    Mei-Yin C. Polley
    Kelly Y. Kim
    James V. Tricoli
    Jeremy M. G. Taylor
    Deborah J. Shuman
    Richard M. Simon
    James H. Doroshow
    Barbara A. Conley
    Nature, 2013, 502 : 317 - 320
  • [4] Criteria for the use of omics-based predictors in clinical trials: explanation and elaboration
    McShane, Lisa M.
    Cavenagh, Margaret M.
    Lively, Tracy G.
    Eberhard, David A.
    Bigbee, William L.
    Williams, P. Mickey
    Mesirov, Jill P.
    Polley, Mei-Yin C.
    Kim, Kelly Y.
    Tricoli, James V.
    Taylor, Jeremy M. G.
    Shuman, Deborah J.
    Simon, Richard M.
    Doroshow, James H.
    Conley, Barbara A.
    BMC MEDICINE, 2013, 11
  • [5] Criteria for the use of omics-based predictors in clinical trials: explanation and elaboration
    Lisa M McShane
    Margaret M Cavenagh
    Tracy G Lively
    David A Eberhard
    William L Bigbee
    P Mickey Williams
    Jill P Mesirov
    Mei-Yin C Polley
    Kelly Y Kim
    James V Tricoli
    Jeremy MG Taylor
    Deborah J Shuman
    Richard M Simon
    James H Doroshow
    Barbara A Conley
    BMC Medicine, 11
  • [6] Where Are All the New Omics-Based Tests?
    Bossuyt, Patrick M.
    CLINICAL CHEMISTRY, 2014, 60 (10) : 1256 - 1257
  • [7] Statistical principles for omics-based clinical trials
    Sachs, Michael C.
    CHINESE CLINICAL ONCOLOGY, 2015, 4 (03)
  • [8] Using omics-based predictors in clinical trials
    不详
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 (01) : 9 - 9
  • [9] Omics-based tests: What is the evidence and how to present it?
    Bogaerts, J.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S1 - S1
  • [10] Omics-Based Platforms: Current Status and Potential Use for Cholangiocarcinoma
    Chang, Yu-Chan
    Chen, Ming-Huang
    Yeh, Chun-Nan
    Hsiao, Michael
    BIOMOLECULES, 2020, 10 (10) : 1 - 25
123